Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2018

View Archived Issues

FDA grants orphan drug designation to Proteostasis Therapeutics' PTI-428

Zymeworks to advance ZW-49 bispecific ADC

Positive topline data from phase III study of ALXN-1210 in patients with PNH

Patient enrollment ongoing in phase II study of BCD-089

PTC Therapeutics provides update on FIREFISH study in spinal muscular atrophy

NGM-282 shown to reduce liver fat in patients with NASH

Massive Bio announces SYNERGY-AI registry

FDA awards breakthrough therapy designation to erdafitinib for metastatic urothelial cancer

Ionis and Akcea enter worldwide license agreement to commercialize inotersen

Exelixis completes submission of sNDA in U.S. for Cabometyx in HCC

Abeona's ABO-202 receives FDA rare pediatic disease designation

Ovid Therapeutics' OV-101 given FDA fast track status

Medshine Discovery discloses novel PDE4 inhibitors

First patient dosed in phase III study of BCX-7353 for HAE

Novartis patents novel CFTR modulators

FDA accepts IND for phase II trial of BPN-14770 in fragile X syndrome

Nanjing TransThera Biosciences divulges novel FGFR inhibitors

Large trial finds mixed effects of carvedilol on chemotherapy-induced cardiotoxicity

Vernalis offers update on restructuring and enters formal sale process

Discuva presents novel antibiotics for bacterial infections

Calibr repurposes leprosy drug for the treatment of cryptosporidiosis

Medivir discovers compounds for RSV infection

Flagship Pioneering announces the launch of Foghorn Therapeutics

Lundbeck agrees to acquire Prexton Therapeutics

Novartis presents novel potent OGG1 inhibitor

CARB-X collaborates with Helixbind to support development of RaPID/BSI diagnostic test

K-mer-based transcriptomic approach identifies new antisense drug targets for Ewing's sarcoma

FDA approves CSL Behring's Hizentra in new indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...